Cyclacel Pharmaceuticals (NASDAQ:BGMS) & Calithera Biosciences (NASDAQ:CALA) Financial Comparison

Calithera Biosciences (NASDAQ:CALA) and Cyclacel Pharmaceuticals (NASDAQ:BGMS) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

Risk & Volatility

Calithera Biosciences has a beta of -1.36, suggesting that its share price is 236% less volatile than the S&P 500. Comparatively, Cyclacel Pharmaceuticals has a beta of -0.38, suggesting that its share price is 138% less volatile than the S&P 500.

Profitability

This table compares Calithera Biosciences and Cyclacel Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Calithera Biosciences	N/A	N/A	N/A
Cyclacel Pharmaceuticals	N/A	-51.21%	-44.00%

Earnings & Valuation

This table compares Calithera Biosciences and Cyclacel Pharmaceuticals”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Calithera Biosciences	N/A	N/A	-$39.65 million	N/A	N/A
Cyclacel Pharmaceuticals	$750,000.00	6.73	-$3.00 million	($4.54)	-0.20

Cyclacel Pharmaceuticals has higher revenue and earnings than Calithera Biosciences.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Calithera Biosciences and Cyclacel Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Calithera Biosciences	0	0	0	0	0.00
Cyclacel Pharmaceuticals	1	0	0	0	1.00

Insider and Institutional Ownership

23.6% of Cyclacel Pharmaceuticals shares are held by institutional investors. 6.6% of Calithera Biosciences shares are held by insiders. Comparatively, 23.7% of Cyclacel Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Cyclacel Pharmaceuticals beats Calithera Biosciences on 6 of the 9 factors compared between the two stocks.

About Calithera Biosciences

Calithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company’s development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing’s disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.